Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

92.89 +2.56 (+2.83%)
Streaming Delayed Price Updated: 11:45 AM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
26 27 Next >
News headline image
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
News headline image
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Cracking The Code: Understanding Analyst Reviews For Incyte ↗
 
Via Benzinga
News headline image
Incyte Breaks Out To 17-Month High As Jakafi Demand Surges ↗
Sales of the company's two key products, Jakafi and Opzelura, jumped. 
Via Investor's Business Daily
News headline image
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
From Incyte
Via Business Wire
News headline image
Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio? ↗
Large-cap stocks had a rough week, including Target, PDD Holdings, ZTO Express, Tenet Healthcare, Ulta Beauty, Intuit, Nokia, Alibaba, Santander, and Incyte. 
Via Benzinga
News headline image
Stock Market Rallies After Key Test; Nvidia, Target, Google, Bitcoin In Focus: Weekly Review ↗
Many leaders flashed buy signals. Bitcoin raced toward $100,000. 
Via Investor's Business Daily
News headline image
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued. ↗
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nasdaq Reverses Losses Amid Nvidia Fanfare ↗
Stocks are attempting to walk back this morning's losses tied to escalating tensions between Russia and Ukraine. 
Via Talk Markets
News headline image
Gold Moves Higher; Medtronic Posts Upbeat Results ↗
 
Via Benzinga
News headline image
Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday? ↗
Wall Street managed to recover from a red start caused by heightened geopolitical tensions stemming from the ongoing Russia-Ukraine conflict. 
Via Benzinga
Topics Energy
News headline image
What's Going On With Incyte Shares Tuesday? ↗
Incyte stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not support further development. 
Via Benzinga
News headline image
Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges ↗
Incyte pauses MRGPRX2 study enrollment due to toxicology concerns, with analysts calling the update disappointing amid pipeline reevaluations. 
Via Benzinga
News headline image
Nasdaq Gains 100 Points; Lowe's Earnings Beat Views ↗
 
Via Benzinga
Topics Earnings
News headline image
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. ↗
The company is discontinuing development of one drug and pausing enrollment in the study of another. 
Via Investor's Business Daily
News headline image
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
News headline image
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock ↗
Incyte reports strong Q3 earnings, driven by Jakafi growth, prompting BofA upgrade with a new price target of $90. 
Via Benzinga
News headline image
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
News headline image
This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura ↗
Incyte reports Q3 revenue of $1.04B, driven by strong Jakafi and Opzelura sales, and raises 2024 guidance amid competitive market challenges. 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.